Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
73
CLYM Quote, Financials, Valuation and Earnings
Last price:
$5.63
Seasonality move
:
38.16%
Day range:
$5.37 - $5.60
52-week range:
$1.05 - $6.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.12x
Volume:
347.8K
Avg. volume:
675K
1-year change:
259.48%
Market cap:
$375M
Revenue:
--
EPS (TTM):
-$0.75
Analysts' Opinion
-
Consensus RatingClimb Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.43, Climb Bio, Inc. has an estimated upside of 107.79% from its current price of $5.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing -45.46% downside risk from its current price of $5.50.
Fair Value
-
According to the consensus of 7 analysts, Climb Bio, Inc. has 107.79% upside to fair value with a price target of $11.43 per share.
CLYM vs. S&P 500
-
Over the past 5 trading days, Climb Bio, Inc. has underperformed the S&P 500 by -0.66% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Climb Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Climb Bio, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Climb Bio, Inc. reported revenues of --.
Earnings Growth
-
Climb Bio, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Climb Bio, Inc. reported earnings per share of -$0.19.
Enterprise value:
288.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.50x
Price / Operating cash flow:
3,451.99x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$67K
Return On Assets:
-25.01%
Net Income Margin (TTM):
--
Return On Equity:
-25.72%
Return On Invested Capital:
-25.66%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -$67K | -- | -$29K | |
| Operating Income | -$44.7M | -$21.2M | -$59.5M | -$8.4M | -$14.9M | |
| EBITDA | -$44.7M | -$21.2M | -$59.4M | -$8.4M | -$14.9M | |
| Diluted EPS | -$1.48 | -$2.13 | -$0.75 | -$0.13 | -$0.19 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $158.6M | $133.2M | $112.4M | $197.6M | $91M | |
| Total Assets | $182.3M | $140.9M | $112.7M | $222.2M | $182.3M | |
| Current Liabilities | $5.6M | $6.3M | $2.9M | $3.4M | $4.9M | |
| Total Liabilities | $5.6M | $6.5M | $3M | $3.4M | $5.3M | |
| Total Equity | $176.7M | $134.4M | $109.7M | $218.8M | $177M | |
| Total Debt | -- | $219K | $58K | -- | $352K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28.1M | -$11M | -$44.2M | -$7.6M | -$12.1M | |
| Cash From Investing | $46.5M | -$30.9M | -$76.1M | -$71.8M | $15.3M | |
| Cash From Financing | $553K | $131M | $41K | $2.3M | -- | |
| Free Cash Flow | -$28.1M | -$11M | -$44.4M | -$7.6M | -$12.2M | |
CLYM
Sector
Market Cap
$375M
$25.8M
Price % of 52-Week High
88.43%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-0.1%
-1.67%
1-Year Price Total Return
259.48%
-21.92%
Beta (5-Year)
--
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.54
200-day SMA
Buy
Level
$2.34
Bollinger Bands (100)
Buy
Level
1.69 - 4.51
Chaikin Money Flow
Sell
Level
-182.2K
20-day SMA
Buy
Level
$5.12
Relative Strength Index (RSI14)
Buy
Level
57.93
ADX Line
Buy
Level
25.07
Williams %R
Neutral
Level
-39.7757
50-day SMA
Buy
Level
$4.27
MACD (12, 26)
Buy
Level
1.38
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Sell
Level
-654.9K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.6257)
Buy
CA Score
(Annual)
Level (0.9721)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (23.7138)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
Stock Forecast FAQ
In the current month, CLYM has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLYM average analyst price target in the past 3 months is $11.43.
-
Where Will Climb Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Climb Bio, Inc. share price will rise to $11.43 per share over the next 12 months.
-
What Do Analysts Say About Climb Bio, Inc.?
Analysts are divided on their view about Climb Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Climb Bio, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Climb Bio, Inc.'s Price Target?
The price target for Climb Bio, Inc. over the next 1-year time period is forecast to be $11.43 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLYM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Climb Bio, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CLYM?
You can purchase shares of Climb Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Climb Bio, Inc. shares.
-
What Is The Climb Bio, Inc. Share Price Today?
Climb Bio, Inc. was last trading at $5.63 per share. This represents the most recent stock quote for Climb Bio, Inc.. Yesterday, Climb Bio, Inc. closed at $5.50 per share.
-
How To Buy Climb Bio, Inc. Stock Online?
In order to purchase Climb Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CLYM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLYM
Sector
P/E ratio
--
23.35x
PEG ratio
--
-0.01x
P/B ratio
2.12x
1.78x
Price / LTM sales
--
1.55x
Growth Metrics
CLYM
Sector
Revenue growth
--
3.74%
Earnings growth
-42.8%
11.14%
Revenue (5-year growth)
--
6.38%
Earnings forecast
-$0.21
-$0.19
Profitability
CLYM
Sector
Profitability FY 2024
--
$2.6M
Return on invested capital
-25.66%
-32.91%
Return on assets
-25.01%
-29.56%
Return on equity
-25.72%
-38.66%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Feb
19
Estimated Next Earnings Date
May
21
Balance Sheet
CLYM
Sector
Total cash
$86.9M
$25.2M
Short term investments
$63.7M
$24.1M
Total assets
$217.2M
$72.8M
Long term debt
$352K
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 19
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
